Lilly(US:LLY) Zheng Quan Ri Bao Wang·2025-10-16 04:14Core Insights - Drug innovation is becoming a significant force in improving diabetes treatment levels, with Eli Lilly's oral GLP-1 drug orforglipron achieving primary and all key secondary endpoints in two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5 [1][2] Group 1: Clinical Trial Results - In the ACHIEVE-2 study, orforglipron demonstrated a significant advantage over dapagliflozin, reducing HbA1c by 1.7% compared to 0.8% for dapagliflozin, targeting patients with poor blood sugar control after metformin treatment [1][2] - The ACHIEVE-5 study focused on more complex diabetes patients, showing that orforglipron combined with insulin glargine resulted in an additional HbA1c reduction of 2.1% compared to placebo, providing a strong potential treatment option for this patient group [2] Group 2: Drug Development and Future Plans - Eli Lilly plans to submit orforglipron for regulatory approval for type 2 diabetes treatment in 2026, with the potential to become an important addition to the diabetes treatment landscape, especially for patients with poor blood sugar control [3] - The company also anticipates completing the submission for orforglipron's obesity treatment indication by the end of this year [3] Group 3: Patient-Centric Approach - The oral formulation of orforglipron, requiring only once-daily dosing without strict dietary restrictions, addresses adherence challenges in diabetes management, reflecting a patient-centered research philosophy [2]